ClinicalTrials.gg

Program

Z 338

Also written as “Z-338”, “YM443” and “Acotiamide hydrochloride hydrate”.

Its studies are mostly in Dyspepsia, led by 3 companies.

Furthest: phase 3, since Sep 25, 200812 company-led studies, 1 open or runningNext primary completion: Dec 30, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Zeria Pharmaceutical70 open or runningphase 3since Sep 25, 2008Feb 28, 2006none ahead
Astellas Pharma40 open or runningphase 3since Sep 30, 2008Jan 26, 2005none ahead
Getz Pharma11 open or runningphase 3since Sep 12, 2025Sep 12, 2025Dec 30, 2026phase 3 · NCT07174297

Also a collaborator on its studies: astellas-pharma-us-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 26, 2005First study: phase 2 study in DyspepsiaNew to Astellas PharmaAstellas Pharma · NCT00102310 · 416 enrolled · United States
  2. Feb 28, 2006Zeria Pharmaceutical's first study: phase 2 study in DyspepsiaNew to Zeria PharmaceuticalZeria Pharmaceutical · NCT00298194 · 52 enrolled · Australia
  3. May 8, 2006Phase 2 study in Functional DyspepsiaZeria Pharmaceutical · NCT00323817 · 282 enrolled · Belgium
  4. Jun 2, 2006Phase 2 study in Functional DyspepsiaZeria Pharmaceutical · NCT00333372 · 440 enrolled · Japan
  5. Apr 9, 2007Phase 2 study in Functioanl DyspepsiaZeria Pharmaceutical · NCT00458328 · 40 enrolled · Japan
  6. Sep 25, 2008Phase 3 study in Functional DyspepsiaZeria Pharmaceutical · NCT00761358 · 820 enrolled · Japan
  7. Sep 30, 2008Phase 3 study in DyspepsiaAstellas Pharma · NCT00764374 · 412 enrolled · Japan
  8. Feb 23, 2009Phase 1 study in Functional DyspepsiaAstellas Pharma · NCT00850746 · 80 enrolled · United States
  9. Jun 15, 2009Phase 1 study in HealthyAstellas Pharma · NCT00920998 · 30 enrolled · Japan
  10. Oct 26, 2013Phase 3 study in DyspepsiaZeria Pharmaceutical · NCT01973790 · 207 enrolled · Belgium, Bulgaria, Latvia and more
  11. Aug 19, 2020Phase 3 study in Functional DyspepsiaZeria Pharmaceutical · NCT04526119 · 55 enrolled · Japan
  12. Sep 12, 2025Getz Pharma's first study: phase 3 study in Postprandial Distress SyndromeNew to Getz PharmaGetz Pharma · NCT07174297 · 152 planned

Ahead

  1. Dec 30, 2026Primary completion: phase 3 study in Postprandial Distress SyndromeGetz Pharma · NCT07174297

TargetBeta

ACHE →read by rule
“Acetylcholinesterase inhibitor”ChEMBL 37, by rule

Other programs on ACHE

ProgramCompanyFurthest phaseStudies
DonepezilruleEisaiphase 483
huperzine Arulewanbangde-pharmaceutical-group-co-ltdphase 47
benzgalantamine gluconaterulealpha-cognition-incphase 41

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07174297Postprandial Distress Syndrome3Not yet recruitingGetz PharmaDec 30, 2026152
NCT04526119Functional Dyspepsia · Japan3CompletedZeria PharmaceuticalMar 2, 202655
NCT01973790Dyspepsia · Belgium, Bulgaria, Latvia and more3CompletedZeria PharmaceuticalNov 2016207
NCT00920998Healthy · Japan1CompletedAstellas PharmaJun 200930
NCT00850746Functional Dyspepsia · United States1CompletedAstellas PharmaApr 200980
NCT00764374Dyspepsia · Japan3CompletedAstellas PharmaDec 2009412
NCT00761358Functional Dyspepsia · Japan3CompletedZeria PharmaceuticalJun 2010820
NCT00458328Functioanl Dyspepsia · Japan2CompletedZeria PharmaceuticalSep 200940
NCT00333372Functional Dyspepsia · Japan2CompletedZeria Pharmaceutical440
NCT00323817Functional Dyspepsia · Belgium2CompletedZeria PharmaceuticalApr 2009282
NCT00298194Dyspepsia · Australia2CompletedZeria PharmaceuticalJul 200852
NCT00102310Dyspepsia · United States2CompletedAstellas PharmaMar 11, 2006416

How it is read

Names in the registry

  • “Z-338”, 7 entries
  • “YM443”, 3 entries
  • “Acotiamide hydrochloride hydrate”, 1 entry
  • “Acotiamide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.